Characteristics of the combination paclitaxel plus doxorubicin in breast cancer cell lines analyzed with the ATP-Cell Viability Assay

SummaryPreliminary clinical data show promising activity regarding the combination of paclitaxel (TaxolTM) (TAX) and doxorubicin (AdriamycinTM) (ADR) in the treatment of breast cancer. This combination needs both further preclinical and clinical investigations to better understand the drug interaction, and to optimize the dose and schedule of these drugs. This study was done to evaluate the combination effect of TAX and ADR in three human breast cancer cell lines. The ATP-Cell-Viability Assay was used to evaluate the chemosensitivity profiles and to obtain dose response curves. For quantitation of synergism and antagonism the median-effect principle was applied and the corresponding combination index values were calculated. Drug synergism/antagonism was shown to be dose-related; synergism was enhanced at higher fractions affected. From this preclinical data, we have concluded that TAX-ADR is highly effective and partly synergisticin vitro. In spite of severe initial toxicities in early clinical trials in metastatic breast cancer patients, further clinical studies appear to be justified in order to define a tolerable dosage.

[1]  J. Garber,et al.  Comprehensive management of disseminated breast cancer , 1990, Cancer.

[2]  J. Emerman.  In Vitro Predictive Sensitivity Testing in the Therapeutic Assessment of Breast Cancer , 1989 .

[3]  Y. Maehara,et al.  [In vitro chemosensitivity testing evaluated by intracellular ATP level: ATP assay]. , 1986, Gan to kagaku ryoho. Cancer & chemotherapy.

[4]  B. Sevin,et al.  Application of an ATP-bioluminescence assay in human tumor chemosensitivity testing. , 1988, Gynecologic oncology.

[5]  W. McGuire,et al.  A simple polymerase chain reaction method for detection and cloning of low-abundance transcripts. , 1990, BioTechniques.

[6]  Y. Maehara,et al.  [Comparison between the succinate dehydrogenase inhibition test and ATP assay for in vitro chemosensitivity testing]. , 1987, Gan to kagaku ryoho. Cancer & chemotherapy.

[7]  F.A.C.P. Gabriel N. Hortobagyi M.D..  Overview of new treatments for breast cancer , 2005, Breast Cancer Research and Treatment.

[8]  B. Sevin,et al.  Comparative evaluation of single and combination chemotherapy in uterine cancer cell lines. , 1991, Gynecologic oncology.

[9]  T. Hattori,et al.  The indications of chemosensitivity tests against various anticancer agents , 1988, The Japanese journal of surgery.

[10]  B. Sevin,et al.  The effects of Provera on chemotherapy of uterine cancer cell lines. , 1991, Gynecologic oncology.

[11]  H. Ichihashi,et al.  [A new chemosensitivity test for cancer cells by measuring intracellular ATP content]. , 1988, Nihon Geka Gakkai zasshi.

[12]  Y. Maehara,et al.  Comparison of the chemosensitivity of human neoplastic tissues between succinate dehydrogenase inhibition test and ATP assay. , 1987, Clinica chimica acta; international journal of clinical chemistry.

[13]  L. Kangas,et al.  Bioluminescence of cellular ATP: a new method for evaluating cytotoxic agents in vitro. , 1984, Medical biology.

[14]  I. Fidler.  Review: Biologic heterogeneity of cancer metastases , 1987, Breast Cancer Research and Treatment.

[15]  N. Komi,et al.  In vitro chemosensitivity testing based on intracellular ATP levels (ATP assay). , 1988, The Tokushima journal of experimental medicine.

[16]  B. Sevin,et al.  The use of ATP bioluminescence assay and flow cytometry in predicting radiosensitivity of uterine cancer cell lines: correlation of radiotoxicity and cell cycle kinetics. , 1992 .

[17]  H. Rumpold,et al.  The Use of Bioluminescence to Evaluate the Influence of Chemotherapeutic Drugs on ATP-Levels of Malignant Cell Lines , 1986, Journal of clinical chemistry and clinical biochemistry. Zeitschrift fur klinische Chemie und klinische Biochemie.

[18]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.

[19]  R B Schifman,et al.  ATP assay: ability to distinguish cytostatic from cytocidal anticancer drug effects. , 1986, Journal of the National Cancer Institute.

[20]  D. Alberts,et al.  Tabular summary of pharmacokinetic parameters relevant to in vitro drug assay. , 1980, Progress in clinical and biological research.

[21]  H. Averette,et al.  Characterization of in vitro chemosensitivity of perioperative human ovarian malignancies by adenosine triphosphate chemosensitivity assay. , 1991, American journal of obstetrics and gynecology.

[22]  B. Sevin,et al.  Chemosensitivity testing in ovarian cancer , 1993, Cancer.

[23]  M. Nishiyama,et al.  A novel in vitro chemosensitivity test using materials collected by endoscopic biopsy , 1991, Anti-cancer drugs.

[24]  M. Nishiyama,et al.  [Clinical studies of in vitro chemosensitivity test evaluated by ATP assay of gastrointestinal cancer]. , 1990, Gan to kagaku ryoho. Cancer & chemotherapy.

[25]  B. Sevin,et al.  The use of ATP bioluminescence assay and flow cytometry in predicting radiosensitivity of uterine cancer cell lines: Correlation of radiotoxicity and cell cycle kinetics , 1993, Gynecologic oncology.

[26]  B. Sevin,et al.  Comparative chemosensitivity profiles in four human ovarian carcinoma cell lines measuring ATP bioluminescence. , 1990, Gynecologic oncology.